Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire

Gelhorn, Heather L.; Dashiell-Aje, Ebony; Miller, Michael G.; Derogatis, Leonard R.; Dobs, Adrian S.; Seftel, Allen D.; Althof, Stanley E.; Brod, Meryl; Revicki, Dennis A.

doi:10.1016/j.jsxm.2016.09.006

Cited by 7 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the correlation coefficient was very low (r = −0.09), but somewhat higher and significant for free testosterone (r = −0.16). Gelhorn, Dashiell‐Aje, et al (2016) reported moderate correlations between the HIS‐Q and total testosterone (r = −0.36). Perhaps this difference between their and our results is due to the fact that they included an older sample of hypogonadal men (mean age 54.1 years), while our sample was on average younger (mean 39.6 years) and included men with a wide range of testosterone levels, from normal to hypogonadal.…”

Section: Discussionmentioning

confidence: 98%

“…For the English HIS‐Q‐SF original, Gelhorn, Dashiell‐Aje, et al (2016) have demonstrated responsiveness to testosterone substitution. This was not part of the design of the study presented here, which could be an area for future research.…”

Section: Discussionmentioning

confidence: 99%

“…Power analysis: Based on Gelhorn, Bodhani, et al (2016), Gelhorn, Dashiell‐Aje, et al (2016) and personal communications with the author, we expected a true correlation of 0.72 between the HIS‐Q‐SF‐D total score and the AMS total score and a correlation of −0.32 between the HIS‐Q‐SF‐D total score and testosterone. For these assumptions, H1 and H2 were to be confirmed with a power of >90 if the study included n = 100 participants; the global power, that is, the probability of confirming both hypotheses, was calculated as 85%.…”

Section: Methodsmentioning

confidence: 99%

“…An English questionnaire named ‘Hypogonadism Impact of Symptoms’ (HIS‐Q), appropriate for both younger and older males has recently been developed in the US, but has not been available in German up to now. The ‘Hypogonadism Impact of Symptoms Questionnaire’ (HIS‐Q) long form (28 items), and its short form (17 items) (HIS‐Q‐SF) have been demonstrated to have good psychometric properties (Gelhorn, Bodhani, et al, 2016; Gelhorn, Dashiell‐Aje, et al, 2016; Gelhorn, Vernon, et al, 2016; Gelhorn et al, 2017). It has been developed for symptom monitoring, not as a diagnostic tool.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

German version of the Hypogonadism Impact of Symptoms Questionnaire: Psychometric properties and association with testosterone levels

et al. 2022

View full text Add to dashboard Cite

The diagnosis 'male hypogonadism' is used to describe a disturbance of testicular endocrine function. It is characterized by symptoms of androgen deficiency in combination with low-serum concentration of testosterone in males of all ages (Bhasin et al.2018;Corona et al., 2020;Dohle et al., 2018). Approximately 6% of middle-aged males are affected (Araujo et al., 2007). Symptoms of androgen deficiency include sexual, somatic, psychological and cognitive symptoms (Corona et al., 2020;Zitzmann et al., 2020).The assessment of symptoms of hypogonadism in clinical practice is difficult, due to patients` discomfort in reporting their complaints. Therefore, a questionnaire filled in by the patient outside the consultation room that is able to detect and monitor symptoms of hypogonadism would be of diagnostic and therapeutic help. In German speaking countries, the 'Aging Males' Symptom Scale (AMS)'

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

German version of the Hypogonadism Impact of Symptoms Questionnaire: Psychometric properties and association with testosterone levels

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Testosterone replacement therapy is a safe and effective therapy for the prevention of morbidity associated with this condition 6. Literature increasing on the use of androgenic anabolic steroids makes us think some users may develop aggression such as mood disorder, hypomania, restlessness and depressive episodes 7. It can be often seen that athletes using anabolic androgenic steroids have psychiatric symptoms and disorders.…”

Section: Discussionmentioning

confidence: 99%

Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement

Elboğa

Sayıner

2018

BMJ Case Reports

View full text Add to dashboard Cite

Hypogonadotropic hypogonadism is a rare congenital disorder characterised by the deficiency and the absence of puberty and infertility. It is caused by the deficient production, secretion or action of gonadotropin-releasing hormone, which is the master hormone regulating the reproductive axis. Gonadotropin-releasing hormone or gonadotropin injections and testosterone replacement therapy are required in the treatment of this disorder. Psychiatric symptoms and disorders may be seen with the use of anabolic androgenic steroids. In this case report, we present a case report in which a patient had behavioural symptoms in childhood and develops bipolar disorder after testosterone replacement therapy. This patient was reached to the remission by increasing the doses of psychiatric drugs without interfering with hormonal therapy. It should be considered that patients receiving testosterone replacement therapy may develop bipolar disorder or trigger mood changes in bipolar mood disease, so behavioural and mood state changes should be closely followed in patients who have bipolar mood disease.

show abstract

Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism

Pencina,

Travison,

Artz

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceTestosterone deficiency causes mild anemia. Whether testosterone replacement therapy (TRT) can correct anemia or prevent the development of anemia in men with hypogonadism remains incompletely understood.ObjectiveTo assess the efficacy of TRT in correcting anemia in men with hypogonadism and anemia, and reducing the risk of developing anemia in those without anemia.Design, Setting, and ParticipantsThis randomized, placebo-controlled trial included men with hypogonadism at 316 US sites enrolled between May 2018 and February 2022. This study was nested within the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) Study, which evaluated the effect of TRT on major adverse cardiovascular events in middle-aged and older men with hypogonadism. Eligible participants were aged 45 to 80 years, with 2 testosterone concentration results below 300 ng/dL, hypogonadal symptoms, and cardiovascular disease (CVD) or increased CVD risk. The last study visit took place in January 2023. Data were analyzed between March and August 2023.InterventionParticipants were randomized with stratification for preexisting CVD to 1.62% testosterone gel or placebo gel daily for the study duration.Main Outcomes and MeasuresProportion of participants with anemia (hemoglobin below 12.7 g/dL) whose anemia remitted (hemoglobin 12.7 g/dL or above) over the study duration. Secondary end points included incidence of anemia among men who were not anemic. Binary end points were analyzed using repeated-measures log-binomial regression.ResultsA total of 5204 men were included, 815 with anemia (mean [SD] age, 64.8 [7.7] years; 247 Black [30.3%], 544 White [66.7%], 24 other [2.9%]) and 4379 without anemia (mean [SD] age, 63.0 [7.9] years; 629 Black [14.4%], 3603 White [82.3%], 147 other [3.4%]). Anemia corrected in a significantly greater proportion of testosterone-treated than placebo-treated men at 6 months (143 of 349 [41.0%] vs 103 of 375 [27.5%]), 12 months (152 of 338 [45.0%] vs 122 of 360 [33.9%]), 24 months (124 of 290 [42.8%] vs 95 of 307 [30.9%]), 36 months (94 of 216 [43.5%] vs 76 of 229 [33.2%]), and 48 months (41 of 92 [44.6%] vs 38 of 97 [39.2%]) (P = .002). Among participants without anemia, a significantly smaller proportion of testosterone-treated men developed anemia than placebo-treated men. Changes in hemoglobin were associated with changes in energy level.Conclusions and RelevanceIn middle-aged and older men with hypogonadism and anemia, TRT was more efficacious than placebo in correcting anemia. Among men who were not anemic, a smaller proportion of testosterone-treated men developed anemia than placebo-treated men.Trial RegistrationClinicalTrials.gov Identifier: NCT03518034

show abstract

Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire

Abstract: The final 28-item HIS-Q is reliable, valid, and responsive. The HIS-Q is suitable for inclusion in future clinical trials to help characterize the effects of testosterone replacement therapy.

Cited by 7 publications

References 14 publications

German version of the Hypogonadism Impact of Symptoms Questionnaire: Psychometric properties and association with testosterone levels

German version of the Hypogonadism Impact of Symptoms Questionnaire: Psychometric properties and association with testosterone levels

Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement

Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism

Contact Info

Product

Resources

About